Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 3/20 | 0.34 |
| ▸ | ATP4B | P51164 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815255 | 0.82 | RET (0.36) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL4731101 | 0.82 | RET (0.36) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL4733704 | 0.79 | L3MBTL1 (0.36) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL5557163 | 0.78 | ATP4A (0.35) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL6487366 | 0.78 | ATP4A (0.35) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL4981356 | 0.77 | ATP4A (0.35) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL5652760 | 0.76 | ATP4A (0.32) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL5032825 | 0.74 | CYP19A1 (0.50) | ATP4AATP4B | |
| SCHEMBL4985180 | 0.70 | ATP4A (0.36) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL4591277 | 0.70 | ATP4A (0.36) | ATP4AATP4BCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286999-B1 | PYRANO[2,3-c]IMIDAZO[1,2-a]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | NYCOMED GMBH (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-6936623-B2 | Pyrano[2,3-C]imidazo[-1,2-A]pyridine derivatives for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040180920-A1 | Pyrano[2,3-C]imidazo[-1,2-A]pyridine derivatives for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2004-09-16 | — | — | US | disclosed |
| US-20030100578-A1 | Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2003-05-29 | — | — | US | disclosed |
| EP-1286999-A1 | PYRANO[2,3-c]IMIDAZO[1,2-a]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA Pharma AG (DE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001072755-A1 | PYRANO[2,3-C]IMIDAZO[-1,2-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100578-A1 | Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders | ALPI, GIPR, SLC10A2 | ATP4A 618/4885ATP4B 1962/4885CYP3A4 67/4885 |
| US-20040180920-A1 | Pyrano[2,3-C]imidazo[-1,2-A]pyridine derivatives for the treatment of gastrointestinal disorders | ALPI, GIPR, SLC10A2 | ATP4A 612/4885ATP4B 2007/4885CYP3A4 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.